ESMO Virtual Congress 2020 Kidney Cancer

Viewing 1-20 of 30 articles

ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Results from Cohort 10 of the COSMIC-021 Study

ESMO Virtual Congress 2020: COSMIC-021, Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma

ESMO Virtual Congress 2020: Invited Discussant (702O) the COSMIC-021 Trial and (LBA25) the French BIONIKK Trial

ESMO Virtual Congress 2020: Results From the Phase 2 BIOmarker Driven Trial with Nivolumab and Ipilimumab or VEGFR TKI in Naïve Metastatic Kidney Cancer: the BIONIKK Trial

ESMO Virtual Congress 2020: Kidney Cancer First-Line Treatment Clinical Trials: Invited Discussant (702O) the COSMIC-021 Trial and (LBA25) the French BIONIKK Trial

ESMO Virtual Congress 2020: Invited Discussant: Predictive Biomarkers in Metastatic Renal Cell Carcinoma

ESMO Virtual Congress 2020: Clear Cell Renal Cell Carcinoma Immune Classification Enhances the Predictive Value of T Effector and Angiogenesis Signatures in Response to Nivolumab

ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor DNA in 847 Patients with Metastatic Renal Cell Carcinoma and Concordance with Tissue-Based Testing

ESMO Virtual Congress 2020: Results from the Phase 2 Biomarker Driven Trial with Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naïve Metastatic Kidney Cancer Patients: The BIONIKK Trial

ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results from the COSMIC-021 Study

ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor DNA in 847 Patients with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing

ESMO Virtual Congress 2020: Predictive Biomarkers in Renal Cell Carcinoma

ESMO Virtual Congress 2020: Kidney ccRCC Immune Classification Enhances the Predictive Value of T Effector and Angiogenesis Signatures in Response to Nivolumab

ESMO Virtual Congress 2020: First Results From the Randomized Phase 3 CheckMate 9ER Trial: Nivolumab + Cabozantinib vs Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma

ESMO Virtual Congress 2020: Comparison of Long-Term Survival and Cost-Effectiveness of First-Line Treatment Options in Advanced Renal Cell Carcinoma with Intermediate or Poor Prognostic Risk

ESMO Virtual Congress 2020: A Phase II Study of Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC) Receiving Pazopanib After Previous Checkpoint Inhibitor Treatment

ESMO Virtual Congress 2020: Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lind Disease–Associated Clear Cell Renal Cell Carcinoma

ESMO Virtual Congress 2020: Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lind Disease–Associated Clear Cell Renal Cell Carcinoma: Update on RCC and Non-RCC Disease

ESMO Virtual Congress 2020: Invited Discussant: First Results From the Randomized Phase 3 CheckMate 9ER Trial

ESMO Virtual Congress 2020: Nivolumab + Cabozantinib vs Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma: First Results From The Randomized Phase 3 CheckMate 9ER Trial

1
2